Literature DB >> 25899339

Synthesis of four binuclear copper(II) complexes: Structure, anticancer properties and anticancer mechanism.

Jinxu Qi1, Shichu Liang2, Yi Gou3, Zhenlei Zhang3, Zuping Zhou2, Feng Yang4, Hong Liang1.   

Abstract

Copper (Cu) compounds are a promising candidate for next generation metal anticancer drugs and have been extensively studied. Therefore, four binuclear copper(II) compounds derived from Schiff base thiosemicarbazones (L1-L4), namely [CuCl(L1)]2 (C1), [CuNO3(L2)]2 (C2), [Cu(NCS) (L3)]2 (C3) and [Cu(CH3COO) (L4)]2 (C4) were synthesized and characterized. Four of these compounds showed very high cytotoxicity to cancer cell lines in vitro. These Cu(II) compounds strongly promoted the apoptosis of BEL-7404 cells. The formation of reactive oxygen species (ROS), change in mitochondrial membrane potential and western blot analysis revealed that Cu compounds could induce cancer cell apoptosis through the intrinsic ROS-mediated mitochondrial pathway accompanied by the regulation of Bcl-2 family proteins.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anticancer activity; Anticancer mechanism; Bcl-2 family proteins; Cell apoptosis; Copper(II) complex

Mesh:

Substances:

Year:  2015        PMID: 25899339     DOI: 10.1016/j.ejmech.2015.04.031

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  6 in total

1.  A novel copper(II) complex identified as a potent drug against colorectal and breast cancer cells and as a poison inhibitor for human topoisomerase IIα.

Authors:  Shayna Sandhaus; Rosella Taylor; Tiffany Edwards; Alexis Huddleston; Ykeysha Wooten; Ramaiyer Venkatraman; Ralph T Weber; Antonio González-Sarrías; Patrick M Martin; Patrice Cagle; Yuk-Ching Tse-Dinh; Stephen J Beebe; Navindra Seeram; Alvin A Holder
Journal:  Inorg Chem Commun       Date:  2016-02       Impact factor: 2.495

2.  In vitro and in vivo anti-proliferative evaluation of bis(4'-(4-tolyl)-2,2':6',2″-terpyridine)copper(II) complex against Ehrlich ascites carcinoma tumors.

Authors:  Dharmasivam Mahendiran; Raju Senthil Kumar; Vijayan Viswanathan; Devadasan Velmurugan; Aziz Kalilur Rahiman
Journal:  J Biol Inorg Chem       Date:  2017-09-07       Impact factor: 3.358

3.  Theoretical and experimental investigation of anticancer activities of an acyclic and symmetrical compartmental Schiff base ligand and its Co(ii), Cu(ii) and Zn(ii) complexes.

Authors:  Lotfali Saghatforoush; Keyvan Moeini; Seyed Abolfazl Hosseini-Yazdi; Zahra Mardani; Alireza Hajabbas-Farshchi; Heather T Jameson; Shane G Telfer; J Derek Woollins
Journal:  RSC Adv       Date:  2018-10-17       Impact factor: 4.036

4.  Cytotoxic effect, generation of reactive oxygen/nitrogen species and electrochemical properties of Cu(ii) complexes in comparison to half-sandwich complexes of Ru(ii) with aminochromone derivatives.

Authors:  Paulina Mucha; Pawel Hikisz; Krzysztof Gwoździński; Urszula Krajewska; Andrzej Leniart; Elzbieta Budzisz
Journal:  RSC Adv       Date:  2019-10-08       Impact factor: 4.036

Review 5.  Advances in thiosemicarbazone metal complexes as anti-lung cancer agents.

Authors:  Xian-Guang Bai; Yunyun Zheng; Jinxu Qi
Journal:  Front Pharmacol       Date:  2022-09-27       Impact factor: 5.988

6.  Cu(ii), Ga(iii) and In(iii) complexes of 2-acetylpyridine N(4)-phenylthiosemicarbazone: synthesis, spectral characterization and biological activities.

Authors:  Yu-Ting Wang; Yan Fang; Meng Zhao; Ming-Xue Li; Yu-Mei Ji; Qiu-Xia Han
Journal:  Medchemcomm       Date:  2017-10-09       Impact factor: 3.597

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.